S

Shanghai Junshi Biosciences Co Ltd
SSE:688180

Watchlist Manager
Shanghai Junshi Biosciences Co Ltd
SSE:688180
Watchlist
Price: 36.7 CNY 0.77% Market Closed
Market Cap: 36.2B CNY

Shanghai Junshi Biosciences Co Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Shanghai Junshi Biosciences Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai Junshi Biosciences Co Ltd
SSE:688180
Revenue
ÂĄ1.9B
CAGR 3-Years
-21%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Revenue
ÂĄ27.2B
CAGR 3-Years
53%
CAGR 5-Years
56%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Revenue
ÂĄ11.4B
CAGR 3-Years
36%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Revenue
ÂĄ2.1B
CAGR 3-Years
111%
CAGR 5-Years
97%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Revenue
ÂĄ2.2B
CAGR 3-Years
-27%
CAGR 5-Years
14%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Revenue
ÂĄ1.9B
CAGR 3-Years
291%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shanghai Junshi Biosciences Co Ltd
Glance View

Market Cap
37.7B CNY
Industry
Biotechnology

Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. emerged as a dynamic player in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of innovative therapies. This company, based in Shanghai, China, has carved a niche in the highly competitive field through its robust pipeline of monoclonal antibodies, small molecule drugs, and therapeutic vaccines. Junshi Biosciences prides itself on its comprehensive R&D capabilities, operating state-of-the-art research facilities that foster significant scientific advancements. Central to its growth strategy is an ongoing commitment to addressing unmet medical needs in oncology, autoimmune, metabolic diseases, and beyond, positioning itself at the forefront of precision medicine. Junshi Biosciences generates revenue through a multifaceted business model that includes partnering with top-tier global pharmaceutical companies, engaging in strategic licensing agreements, and advancing its proprietary products through various stages of clinical trials to eventual market launch. A landmark achievement for the company was the development and commercialization of Toripalimab, China's first domestically developed anti-PD-1 monoclonal antibody approved for multiple indications, which marked a significant milestone in its financial trajectory. Such breakthroughs not only bolster its top-line revenue but also solidify its reputation as an innovator in the global biotechnology landscape. By blending scientific ingenuity with strategic collaborations, Junshi continues to expand its international footprint and deepen its impact on global health.

Intrinsic Value
34.94 CNY
Overvaluation 5%
Intrinsic Value
Price
S

See Also

What is Shanghai Junshi Biosciences Co Ltd's Revenue?
Revenue
1.9B CNY

Based on the financial report for Dec 31, 2024, Shanghai Junshi Biosciences Co Ltd's Revenue amounts to 1.9B CNY.

What is Shanghai Junshi Biosciences Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
20%

Over the last year, the Revenue growth was 30%. The average annual Revenue growth rates for Shanghai Junshi Biosciences Co Ltd have been -21% over the past three years , 20% over the past five years .

Back to Top